Daratumumab
- Generic Name
- Daratumumab
- Brand Names
- Darzalex, Darzalex Faspro
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 945721-28-8
- Unique Ingredient Identifier
- 4Z63YK6E0E
- Background
Daratumumab is an immunoglobulin G1 kappa monoclonal antibody developed by Janssen and Genmab. It was first described in the literature in 2010 as a monoclonal antibody that targets CD38+ multiple myeloma cells; the first of its kind.
...
- Indication
Daratumumab is indicated as an intravenous injection alone or in combination with other medications for the treatment of multiple myeloma. It is available as a combination product with hyaluronidase for the treatment of adults with multiple myeloma as monotherapy or combination therapy and light chain amyloidosis in combination with other drugs.
- Associated Conditions
- Multiple Myeloma (MM), Primary Amyloidosis, Refractory Multiple Myeloma, Relapsed Multiple Myeloma
- Associated Therapies
- -
A Study to Determine Dose, Safety, Tolerability, Drug Levels, and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Participants With Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2016-05-16
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- Celgene
- Target Recruit Count
- 466
- Registration Number
- NCT02773030
- Locations
- 🇺🇸
Local Institution - 101, Atlanta, Georgia, United States
🇺🇸Local Institution - 108, Hackensack, New Jersey, United States
🇺🇸Local Institution - 115, Boston, Massachusetts, United States
Study of Daratumumab in Combination With Dexamethasone in Resistant or Refractory Multiple Myeloma
- First Posted Date
- 2015-12-10
- Last Posted Date
- 2021-03-26
- Lead Sponsor
- University Hospital, Lille
- Target Recruit Count
- 64
- Registration Number
- NCT02626481
- Locations
- 🇧🇪
AZ ST Jan hematology department, Bruges, Belgium
🇧🇪Hematologie Laarbeeklaan, Brussel, Belgium
🇧🇪Jules Bordet Institute, Brussel, Belgium
A Study to Evaluate Daratumumab in Transplant Eligible Participants With Previously Untreated Multiple Myeloma
- First Posted Date
- 2015-09-04
- Last Posted Date
- 2020-12-07
- Lead Sponsor
- Intergroupe Francophone du Myelome
- Target Recruit Count
- 1085
- Registration Number
- NCT02541383
- Locations
- 🇫🇷
Centre Léon Bérard, Lyon, France
🇧🇪AZ St Jan Brugge Oostende AV, Brugge, Belgium
🇧🇪UZ Brussel, Bruxelles, Belgium
An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors
- Conditions
- Interventions
- First Posted Date
- 2015-07-02
- Last Posted Date
- 2023-11-13
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 578
- Registration Number
- NCT02488759
- Locations
- 🇺🇸
Local Institution - 0003, Atlanta, Georgia, United States
🇧🇪Local Institution - 0012, Brussels, Belgium
🇺🇸Local Institution - 0033, Tampa, Florida, United States
Early Access Treatment With Daratumumab for (Relapsed or Refractory) Multiple Myeloma
- Conditions
- First Posted Date
- 2015-06-23
- Last Posted Date
- 2019-01-15
- Lead Sponsor
- Janssen Research & Development, LLC
- Registration Number
- NCT02477891
A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)
- Conditions
- Interventions
- First Posted Date
- 2015-04-30
- Last Posted Date
- 2021-04-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 85
- Registration Number
- NCT02431208
- Locations
- 🇺🇸
University of Maryland School of Medicine, Baltimore, Maryland, United States
🇺🇸Mayo Clinic Hospital - Florida, Jacksonville, Florida, United States
🇺🇸Emory Univ Winship Cancer Inst, Atlanta, Georgia, United States
"Monoclonal Antibodies for Treatment of Multiple Myeloma. Emphasis on the CD38 Antibody Daratumumab "
- Conditions
- Interventions
- First Posted Date
- 2015-04-17
- Last Posted Date
- 2017-11-07
- Lead Sponsor
- Vejle Hospital
- Target Recruit Count
- 4
- Registration Number
- NCT02419118
- Locations
- 🇩🇰
Department of Hematology Vejle Hospital, Vejle, Denmark
An Efficacy and Safety Proof of Concept Study of Daratumumab in Relapsed/Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2015-04-10
- Last Posted Date
- 2018-06-26
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 36
- Registration Number
- NCT02413489
Selinexor and Backbone Treatments of Multiple Myeloma Patients
- First Posted Date
- 2015-01-21
- Last Posted Date
- 2024-05-07
- Lead Sponsor
- Karyopharm Therapeutics Inc
- Target Recruit Count
- 300
- Registration Number
- NCT02343042
- Locations
- 🇺🇸
Sarah Cannon-Colorado Blood Cancer Institute, Denver, Colorado, United States
🇺🇸University of Nebraska Medical Center, Omaha, Nebraska, United States
🇺🇸Swedish Cancer Institute, Seattle, Washington, United States
A Study to Evaluate 3 Dose Schedules of Daratumumab in Participants With Smoldering Multiple Myeloma
- First Posted Date
- 2014-12-12
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 123
- Registration Number
- NCT02316106
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.